Real‐World Data for Safety Studies: Challenges and Opportunities From the Italian Multiple Sclerosis and Related Disorders Register
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Marco Salivetto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy. Hauptthemen laut MEDLINE: Multiple Sclerosis, Registries, Pharmacovigilance, Adverse Drug Reaction Reporting Systems. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Information on the safety profile of disease‐modifying therapies (DMTs) in multiple sclerosis (MS) is often lacking in routine clinical practice. Real‐world data sources, such as patient registries, support pharmacovigilance to characterise safety signals, as recently recognised by regulatory agencies. In Italy, the “Italian Multiple Sclerosis and Related Disorders Register” (RISM) was officially launched in 2015 to collect demographic and clinical data from patients with MS.
Purpose
To describe the main characteristics of RISM as a research platform supporting the safety evaluation of MS therapies.
Methods
RISM enables the systematic characterisation of clinical events occurring in treated patients and, over the years, has implemented procedures to ensure high‐quality data collection. A study cohort including subjects who initiated a DMT between 2016 and 2025 is analysed using descriptive statistics. Clinical events recorded during the study period are reported as absolute numbers and frequencies.
Results
Between 2016 and 2025, a total of 24 259 subjects received at least one DMT, and 4419 of them (18.2%) experienced one or multiple clinical events. For descriptive purposes, the occurrence of infections and malignancies, which accounted for 29.4% and 3.7% of all the clinical events collected in RISM respectively, are reported and categorised.
Conclusions
This article outlines the strengths and limitations of RISM in conducting safety studies and highlights the methodological and legal challenges associated with such platforms. Routinely collected healthcare data within RISM provide a comprehensive, patient‐centred perspective for the long‐term evaluation of DMT safety and can address relevant questions on drug policies and public health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy.
- Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
- Department of Translational Biomedicine and Neurosciences - DiBraiN, University of Bari "Aldo Moro", Bari, Italy.
ORCID-Profile: Marco Salivetto, Tommaso Guerra, Pasquale Paletta, Vito Lepore, Paola Mosconi, Pietro Iaffaldano, Michela Ponzio
Zitieren
APA
Salivetto, M., Guerra, T., Paletta, P., Lepore, V., Mosconi, P., Iaffaldano, P., Ponzio, M., Scientific Committee of the Italian Multiple Sclerosis and Related Disorders Register*, Research Assistant Network of the Italian Multiple Sclerosis and Related Disorders Register**, & Italian Multiple Sclerosis and Related Disorders Register Centres Group*** (2026). Real‐World Data for Safety Studies: Challenges and Opportunities From the Italian Multiple Sclerosis and Related Disorders Register. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70432
Vancouver
Salivetto M, Guerra T, Paletta P, Lepore V, Mosconi P, Iaffaldano P, et al. Real‐World Data for Safety Studies: Challenges and Opportunities From the Italian Multiple Sclerosis and Related Disorders Register. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70432
BibTeX
@article{Salivetto2026,
author = {Salivetto, Marco and Guerra, Tommaso and Paletta, Pasquale and Lepore, Vito and Mosconi, Paola and Iaffaldano, Pietro and Ponzio, Michela and Scientific Committee of the Italian Multiple Sclerosis and Related Disorders Register*, Scientific Committee of the Italian Multiple Sclerosis and Related Disorders Register* and Research Assistant Network of the Italian Multiple Sclerosis and Related Disorders Register**, Research Assistant Network of the Italian Multiple Sclerosis and Related Disorders Register** and Italian Multiple Sclerosis and Related Disorders Register Centres Group***, Italian Multiple Sclerosis and Related Disorders Register Centres Group***},
title = {Real‐World Data for Safety Studies: Challenges and Opportunities From the Italian Multiple Sclerosis and Related Disorders Register},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70432}
}
EUVIMED